Effective 1 September 2024, Sybille Wasmuth, born in East Westphalia, joins the Bielefeld-based Dr. Wolff Group as the new Chief Financial Officer (CFO) member of the management board.
Bringing over 15 years of finance and extensive management experience in the consumer goods industry. She succeeds Dr. Christian Mestwerdt, who left the company at the end of April 2024 after eight years on the Management Board, where he was responsible, inter alia, for the finance division.
Sybille Wasmuth’s career had begun at British American Tobacco in supply chain and controlling before she joined Beiersdorf AG in 2009. She successfully held several controlling and finance management positions, both in Germany and abroad. After working in the UK and Hamburg, she took over responsibility for Eastern Europe as Finance Director in Vienna in 2020. Since 2023, she has been Vice President Finance Pharmacy & Selective Brands in Hamburg, with global responsibility for the finance for brands like Eucerin, Hansaplast, La Prairie, and Chantecaille.
‘We are delighted to have gained Sybille Wasmuth, a highly experienced and dynamic personality who will help us to further develop our structures and processes with strategic foresight,’ says Eduard R. Dörrenberg, Chairman of the Management Board.
“Starting as CFO at Dr. Wolff is an extremely exciting step for me. I am looking forward to working with my colleagues, the brands, and taking on the responsible tasks at the top of the finance department. I am also excited to finally support my home region of East Westphalia trough the Bielefeld location,” emphasizes Sybille Wasmuth.
Sybille Wasmuth completes the management of the Dr. Wolff Group, consisting of Eduard R. Dörrenberg (Chairman of the Management Board and responsible for Research and Development, Marketing, Sales and Human Resources), Christoph Harras-Wolff (Legal, Associations and Sustainability) and Dr. Andreas Brinkhoff (Supply Chain and IT).
Dr. Wolff Group
With brands such as Alcina, Alpecin and Linola, as well as Plantur, Vagisan, Karex and Bioniq®, the Dr. Wolff Group, a fourth-generation family-run company based in Bielefeld, is on a global growth trajectory with almost 900 employees. Since its foundation in 1905, the focus has been on research and the scientifically proven benefits of the products to find solutions for hair or skin problems. With its own developments, the company was able to achieve a turnover of 391.5 million euros in 2023. Dr. Wolff is active in 67 countries.